Molecular Pharmacology Stock Market Value
| MLPH Stock | USD 0.0006 0 85.00% |
| Symbol | Molecular |
Molecular Pharmacology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Pharmacology's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Pharmacology.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Molecular Pharmacology on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Molecular Pharmacology or generate 0.0% return on investment in Molecular Pharmacology over 90 days. Molecular Pharmacology Limited, a development stage company, develops and commercializes pain and inflammation managemen... More
Molecular Pharmacology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Pharmacology's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Pharmacology upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1324 | |||
| Maximum Drawdown | 651.67 | |||
| Potential Upside | 25.0 |
Molecular Pharmacology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Pharmacology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Pharmacology's standard deviation. In reality, there are many statistical measures that can use Molecular Pharmacology historical prices to predict the future Molecular Pharmacology's volatility.| Risk Adjusted Performance | 0.1076 | |||
| Jensen Alpha | 11.96 | |||
| Total Risk Alpha | 2.92 | |||
| Treynor Ratio | (0.30) |
Molecular Pharmacology January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1076 | |||
| Market Risk Adjusted Performance | (0.29) | |||
| Mean Deviation | 22.4 | |||
| Coefficient Of Variation | 749.39 | |||
| Standard Deviation | 72.99 | |||
| Variance | 5327.91 | |||
| Information Ratio | 0.1324 | |||
| Jensen Alpha | 11.96 | |||
| Total Risk Alpha | 2.92 | |||
| Treynor Ratio | (0.30) | |||
| Maximum Drawdown | 651.67 | |||
| Potential Upside | 25.0 | |||
| Skewness | 7.08 | |||
| Kurtosis | 54.24 |
Molecular Pharmacology Backtested Returns
Molecular Pharmacology is out of control given 3 months investment horizon. Molecular Pharmacology has Sharpe Ratio of 0.14, which conveys that the firm had a 0.14 % return per unit of risk over the last 3 months. We were able to interpolate data for nineteen different technical indicators, which can help you to evaluate if expected returns of 10.04% are justified by taking the suggested risk. Use Molecular Pharmacology Risk Adjusted Performance of 0.1076, standard deviation of 72.99, and Mean Deviation of 22.4 to evaluate company specific risk that cannot be diversified away. Molecular Pharmacology holds a performance score of 10 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -32.66, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Molecular Pharmacology are expected to decrease by larger amounts. On the other hand, during market turmoil, Molecular Pharmacology is expected to outperform it. Use Molecular Pharmacology variance, skewness, as well as the relationship between the Skewness and price action indicator , to analyze future returns on Molecular Pharmacology.
Auto-correlation | -0.05 |
Very weak reverse predictability
Molecular Pharmacology has very weak reverse predictability. Overlapping area represents the amount of predictability between Molecular Pharmacology time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Pharmacology price movement. The serial correlation of -0.05 indicates that only as little as 5.0% of current Molecular Pharmacology price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.05 | |
| Spearman Rank Test | 0.66 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Currently Active Assets on Macroaxis
Other Information on Investing in Molecular Pink Sheet
Molecular Pharmacology financial ratios help investors to determine whether Molecular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecular with respect to the benefits of owning Molecular Pharmacology security.